Rocket Pharmaceuticals price target lowered to $47 from $49 at Canaccord

Canaccord analyst Whitney Ijem lowered the firm’s price target on Rocket Pharmaceuticals to $47 from $49 and keeps a Buy rating on the shares. The firm said its 2Q earnings provided an incremental update on their lead cardiovascular program RP-A501 for Danon disease as well as announced a data licensing agreement with Invitae to support genetic testing through the identification of patients with genetic forms of cardiomyopathy.